Once-weekly diabetes drug backed in draft NICE guidance

Once-weekly type-2 diabetes drug exenatide has been recommended for third-line use in draft guidance from NICE.

NICE draft guidance recommends exenatide
NICE draft guidance recommends exenatide

Exenatide prolonged release has been recommended for use with metformin in addition to either a sulphonylurea or a thiazolidinedione. Its use should be restricted to people HbA1c levels above 7.5% and a BMI over 35 or who are unsuitable for insulin therapy, NICE has said.

The draft recommends that long-acting exenatide should only be used for patients unsuitable for triple therapy with any three of: metformin, a sulphonylurea, a thiazolidinedione and a dipeptidyl peptidase-4 inhibitor.

NICE’s draft guidance on long-acting exenatide is open for consultation until 8 November, with final guidance likely to be published in February 2012.

Commenting on the draft decision, Professor Carole Longson, director of the health technology evaluation centre at NICE said: ‘Type-2 diabetes is becoming increasingly more common in adults, so we are pleased to recommend exenatide as a treatment option for some people with the condition.’

Long-acting exenatide is marketed by Eli Lilly as Bydureon suspension for injection.

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women and under-18s will not be offered COVID-19 vaccine

Pregnant women, children and under-18s will not be recommended for routine COVID-19...

GP training: How an audit e-portfolio log entry is assessed

GP training: How an audit e-portfolio log entry is assessed

The second of two articles on audit during GP training looks at how the quality improvement...

GP training: Writing up an audit for your e-portfolio

GP training: Writing up an audit for your e-portfolio

In the first of two articles on how to write up an audit, a typical e-portfolio entry...

UK ups order of 95% effective COVID-19 vaccine by 2m doses

UK ups order of 95% effective COVID-19 vaccine by 2m doses

The UK has increased its order of the 95% effective Moderna COVID-19 vaccine to 7m...

Coronavirus: Key guidance GPs need to know about COVID-19

Coronavirus: Key guidance GPs need to know about COVID-19

GPonline provides an overview of the key guidance relating to coronavirus, including...

Which COVID-19 vaccines are lined up for roll-out on the NHS?

Which COVID-19 vaccines are lined up for roll-out on the NHS?

As GPs and their teams prepare for delivering a COVID-19 vaccination programme that...